

 대한민국 대전환 한국판뉴딜  Ministry of Food and Drug Safety	<h1>Press Release</h1>	Released on	Apr. 12, 2021 (Mon)
		Divisions	첨단제품허가담당관 바이오생약국 바이오의약품품질관리과 백신심사반 총괄검토팀 신종감염병백신검정과
		Directors	정현철 (☎043-719-5351) 문은희 (☎043-719-3651) 김희성 (☎043-719-5061) 오호정 (☎043-719-5494)
		Researchers	남주선 (☎043-719-5354) 지영혜 (☎043-719-3664) 고용석 (☎043-719-5062) 지승완 (☎043-719-5468)

MFDS Begins Review of Moderna COVID-19 Vaccine

- The Ministry of Food and Drug Safety (MFDS, Minister Kim Ganglip) announced that Green Cross Corporation, or GC Pharma, filed an application for the Moderna COVID-19 vaccine's marketing authorization.
- The Moderna COVID-19 vaccine, administered as a two-dose schedule given 28 days apart, is among the vaccines to be distributed in Korea according to the government's national inoculation plan.
 - The Moderna vaccine is an mRNA vaccine manufactured by injecting antigen genes in the form of mRNA for antigen production against SARS-CoV-2, using the same platform as the Pfizer vaccine Comirnaty.
- The MFDS will thoroughly examine the vaccine's safety and efficacy to determine whether to grant a marketing authorization through a rigorous review of quality, non-clinical, clinical and GMP data while carrying out a three-tiered advisory review by the COVID-19 Treatment and Vaccine Safety and Efficacy Assessment Advisory Committee, Central Pharmaceutical Advisory Committee and Final Evaluation Committee.
- The Moderna COVID-19 vaccine has thus far received Emergency Use Authorizations (EUA) in countries including the United Kingdom and United States; and has been granted a conditional approval from the European Union, Canada and Switzerland among others on condition that additional documents be submitted following the approval.